Cite
HARVARD Citation
Bowler, S. et al. (2019). Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. HIV research & clinical practice. 20 (4), pp. 123-129. [Online].